<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yamada Y</submitter><funding>MEXT | Japan Society for the Promotion of Science (JSPS)</funding><funding>Swiss National Science Foundation</funding><funding>Swiss National Science Foundation | nccr - on the move (National Center of Competence in Research - The Migration-Mobility Nexus)</funding><pagination>285</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12182575</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>Although liver kinase B1 (LKB1) has been established as a tumor suppressor kinase, its mechanism of action is incompletely understood. Here we describe a novel nonenzymatic function of LKB1 in cell death induced by Fas/CD95. In BID knockout HeLa cells, inactivation of mitochondrial outer membrane permeabilization (MOMP) prevents Smac-induced inhibition of X-linked inhibitor of apoptosis (XIAP), causing resistance to Fas-induced apoptosis. However, reexpression of LKB1 in those cells naturally deficient for endogenous LKB1 restored apoptosis. Mechanistically, caspase-8 activated by Fas processed LKB1 to a truncated form, tLKB1. Both WT and kinase-inactive LKB1 antagonized XIAP to restore apoptosis, but somatic mutants of LKB1 found in Peutz-Jeghers syndrome (PJS) failed to do so. Thus, in a</pubmed_abstract><journal>Cell death discovery</journal><pubmed_title>Truncated LKB1 nonenzymatically enhances Fas-induced apoptosis by acting as a surrogate of Smac.</pubmed_title><pmcid>PMC12182575</pmcid><funding_grant_id>JP21H00268</funding_grant_id><funding_grant_id>JP24KJ0428</funding_grant_id><funding_grant_id>JP24K02237</funding_grant_id><funding_grant_id>JP18J20440</funding_grant_id><funding_grant_id>205196</funding_grant_id><funding_grant_id>JP24K02173</funding_grant_id><funding_grant_id>JP21H02691</funding_grant_id><funding_grant_id>310030</funding_grant_id><funding_grant_id>310030-205196</funding_grant_id><funding_grant_id>JP21H02620</funding_grant_id><pubmed_authors>Noguchi T</pubmed_authors><pubmed_authors>Tokunaga F</pubmed_authors><pubmed_authors>Mitsuya M</pubmed_authors><pubmed_authors>Yokosawa T</pubmed_authors><pubmed_authors>Shimada T</pubmed_authors><pubmed_authors>Yamada Y</pubmed_authors><pubmed_authors>Schneider P</pubmed_authors><pubmed_authors>Matsuzawa A</pubmed_authors><pubmed_authors>Oikawa D</pubmed_authors><pubmed_authors>Hirata Y</pubmed_authors><pubmed_authors>Tsuchida M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Truncated LKB1 nonenzymatically enhances Fas-induced apoptosis by acting as a surrogate of Smac.</name><description>Although liver kinase B1 (LKB1) has been established as a tumor suppressor kinase, its mechanism of action is incompletely understood. Here we describe a novel nonenzymatic function of LKB1 in cell death induced by Fas/CD95. In BID knockout HeLa cells, inactivation of mitochondrial outer membrane permeabilization (MOMP) prevents Smac-induced inhibition of X-linked inhibitor of apoptosis (XIAP), causing resistance to Fas-induced apoptosis. However, reexpression of LKB1 in those cells naturally deficient for endogenous LKB1 restored apoptosis. Mechanistically, caspase-8 activated by Fas processed LKB1 to a truncated form, tLKB1. Both WT and kinase-inactive LKB1 antagonized XIAP to restore apoptosis, but somatic mutants of LKB1 found in Peutz-Jeghers syndrome (PJS) failed to do so. Thus, in a</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jun</publication><modification>2026-05-29T14:29:03.789Z</modification><creation>2026-04-08T05:03:55.864Z</creation></dates><accession>S-EPMC12182575</accession><cross_references><pubmed>40544190</pubmed><doi>10.1038/s41420-025-02570-1</doi></cross_references></HashMap>